Amphastar Pharmaceuticals, Inc. (AMPH) key performance indicators and operating metrics (9 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Diluted Earnings Per Share | 0.42 USD_per_share | FY2026-Q1 |
| Adjusted Net Income | 19.48M | FY2026-Q1 |
| Epinephrine Net Product Revenue | 19.21M | FY2026-Q1 |
| Glucagon Net Product Revenue | 9.17M | FY2026-Q1 |
| Primatene MIST Net Product Revenue | 29.76M | FY2026-Q1 |
| Lidocaine Net Product Revenue | 13.46M | FY2026-Q1 |
| Other Finished Pharmaceutical Products Net Revenue | 67.13M | FY2026-Q1 |
| BAQSIMI Net Product Revenue | 53.61M | FY2025-Q3 |
| Net Product Revenues | 174.41M | FY2025-Q2 |
Back to AMPH overview · AMPH earnings · AMPH holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.